GlobeNewswire Inc | Feb 18, 2021 04:01PM EST

February 18, 2021

STAMFORD, Conn., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc.(Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced that the Company will host a conference call and live audio webcast on Thursday, February 25, 2021, at 4:30 p.m. ET to report fourth quarter and full year 2020 financial results and provide a corporate update.

To participate in the conference call, please dial (855) 445-2816 (domestic) or (484) 756-4300 (international) and refer to conference ID 6676157. A live webcast of the call can be accessed under Events & Presentations in the News & Investors section of the Companys website at www.CaraTherapeutics.com.

An archived webcast recording will be available on the Cara website beginning approximately two hours after the call.

About Cara Therapeutics

Cara Therapeuticsis a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs. Cara is developing a novel and proprietary class of product candidates, led by KORSUVA (CR845/difelikefalin), a first-in-class KOR agonist that targets the bodys peripheral nervous system, as well as certain immune cells. The Company has submitted a New Drug Application (NDA) to theU.S. Food and Drug Administration(FDA) for KORSUVA Injection (difelikefalin) for the treatment of moderate-to-severe pruritus in hemodialysis patients. KORSUVA Injection received Breakthrough Therapy Designation from the FDA for this indication. Cara has requested Priority Review for the NDA which, if granted, could result in a six-month review process. Oral KORSUVA has successfully completed a Phase 2 trial for the treatment of pruritus in patients with CKD and is currently in Phase 2 trials in atopic dermatitis and primary biliary cholangitis patients with moderate-to-severe pruritus.

The FDA has conditionally accepted KORSUVA as the trade name for difelikefalin injection. CR845/difelikefalin is an investigational drug product and its safety and efficacy have not been fully evaluated by any regulatory authority.

MEDIA CONTACT:Claire LaCagnina6 Degrees315-765-1462clacagnina@6degreespr.com

INVESTOR CONTACT:Janhavi MohiteStern Investor Relations, Inc.212-362-1200 janhavi.mohite@SternIR.com